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TaME-seq: An efficient sequencing 
approach for characterisation 
of HPV genomic variability and 
chromosomal integration
Sonja Lagström1,2, Sinan Uğur Umu  2, Maija Lepistö3, Pekka Ellonen3, Roger Meisal  1, 
Irene Kraus Christiansen1,4, Ole Herman Ambur5 & Trine B. Rounge  2
HPV genomic variability and chromosomal integration are important in the HPV-induced carcinogenic 
process. To uncover these genomic events in an HPV infection, we have developed an innovative 
and cost-effective sequencing approach named TaME-seq (tagmentation-assisted multiplex PCR 
enrichment sequencing). TaME-seq combines tagmentation and multiplex PCR enrichment for 
simultaneous analysis of HPV variation and chromosomal integration, and it can also be adapted to 
other viruses. For method validation, cell lines (n = 4), plasmids (n = 3), and HPV16, 18, 31, 33 and 45 
positive clinical samples (n = 21) were analysed. Our results showed deep HPV genome-wide sequencing 
coverage. Chromosomal integration breakpoints and large deletions were identified in HPV positive 
cell lines and in one clinical sample. HPV genomic variability was observed in all samples allowing 
identification of low frequency variants. In contrast to other approaches, TaME-seq proved to be highly 
efficient in HPV target enrichment, leading to reduced sequencing costs. Comprehensive studies on 
HPV intra-host variability generated during a persistent infection will improve our understanding 
of viral carcinogenesis. Efficient identification of both HPV variability and integration sites will be 
important for the study of HPV evolution and adaptability and may be an important tool for use in 
cervical cancer diagnostics.
Human papillomavirus (HPV) is the main cause of cervical cancer1, one of the most common cancers in women 
worldwide, causing more than 200,000 deaths each year2,3. A persistent infection with HPV high-risk genotypes 
is recognised as a necessary cause of cancer development4. Of the 13 carcinogenic high-risk types, HPV16 and 
18 are associated with about 70% of all cervical cancers5,6. HPV infection is also associated with cancer in penis, 
vulva, vagina, anus, and head and neck7. However, only a small fraction of HPV infections at any site will progress 
to cancer8. This indicates that in addition to HPV infection, additional factors such as HPV genomic variability 
and integration, could contribute to the HPV-induced carcinogenic process. An appropriate sequencing approach 
is needed to uncover these genomic events during a persistent HPV infection.
HPV contains an approximately 7.9 kb circular double-stranded DNA genome, consisting of early region (E1, 
E2, E4-7) genes, late region (L1, L2) genes and an upstream regulatory region (URR)9. To date, more than 200 
HPV types have been identified10. Each individual HPV type shares at least 90% sequence identity in the con-
served L1 open reading frame (ORF) nucleotide sequence. Isolates of the same HPV types that differ by 1–10% or 
0.5–1% across the genome are referred to as variant lineages or sublineages, respectively11,12.
Despite phylogenetic relatedness, HPV variant lineages can differ in their carcinogenic potential13–16. 
Traditionally, studies have focused on cancer risk of main variants. However, recent studies have revealed varia-
bility below the level of variant lineages that may be evidence of intra-host viral evolution and adaptation17–20. In 
contrast to a limited number of studies on HPV variability, HPV integration into the host genome has been more 
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widely studied and is regarded as a determining event in cervical carcinogenesis21–23. Upon integration, disrup-
tion or complete deletion of the E1 or E2 gene is often observed, resulting in constitutive expression of the E6 
and E7 oncogenes24–26, inactivation of cell cycle checkpoints and genetic instability23. Viral integration may also 
lead to modified expression of cellular genes nearby, disruption of genes, as well as genomic amplifications that 
may promote oncogenesis23,27. The finding of certain chromosomal clusters of integration in precancerous lesions 
and cancers28 also suggests a selective advantage of specific HPV integrations. Still, several important questions 
remain for HPV integration and more comprehensive analyses of integration sites are needed in order to expand 
our understanding of HPV pathogenesis.
The development of next generation sequencing (NGS) technologies has provided new tools for viral genomic 
research. During the recent years, a few studies have described different NGS based approaches to study HPV 
variability and integration in the human genome. The most common approaches used in HPV genomic analyses 
are based on target enrichment using highly multiplexed degenerate primers29, enrichment by multiplex PCR 
using HPV16 forward primers30, bead-based target capture31–33, and rolling circle amplification34 followed by 
NGS. These methods are however designed to detect either HPV integration or HPV variability. In addition, tar-
get capture methods poorly enrich HPV and remain expensive due to high probe cost and off-target sequencing.
In order to contribute to the understanding of the role of intra-host HPV genomic variability and chromo-
somal integration in carcinogenesis, we have developed an innovative library preparation strategy followed by an 
in-house bioinformatics pipeline named TaME-seq (tagmentation-assisted multiplex PCR enrichment sequenc-
ing). TaME-seq combines tagmentation and multiplex PCR enrichment, allowing simultaneous HPV genomic 
variability and integration analysis (Fig. 1). TaME-seq, with highly efficient target enrichment and reduced 
sequencing cost, enables deep sequencing analysis in order to find low frequency variants and rare integration 
events. Here, we present the results of HPV integration and genomic variability analysis in HPV16, 18, 31, 33 and 
45 positive clinical samples and cell lines. The method described here provides an important tool for comprehen-
sive studies of HPV genomic variability and chromosomal integration, and it can also be adapted to studies on 
other viruses such as retroviruses, adeno-associated viruses and integrating human herpesviruses.
Results
Read mapping analysis and genome coverage. Table 1 summarises liquid-based cytology (LBC) sam-
ples (n = 21), cell lines (n = 4) and plasmid samples (n = 3) included in the analysis. The samples generated 154.8 
million raw reads of which 72.5 million reads (47%) mapped to the target HPV reference genomes. Only a small 
fraction (0.08%) of the reads mapped to other HPV types than those reported positive by HPV genotyping. The 
mean coverage ranged from 303 to 273898, while the fraction of the genome covered by minimum 10 × ranged 
from 0.35 to 1, and the fraction of the genome covered by minimum 100 × ranged from 0.33 to 1 (Table 1). HPV 
genome sequencing coverage aligned to the target HPV genomes with the location of HPV genomic regions and 
primers is visualised for CaSki, HeLa, LBC34, LBC11 and MS751 (Fig. 2). Overall, the samples showed varying 
HPV genome coverage profiles (Supplementary Figs S1–S5). Totally, 10 HPV positive samples were excluded from 
further analysis due to poor sequencing coverage (Supplementary Table S1). Sequencing of the HPV negative con-
trol samples resulted in no or negligible amount (<500) of reads mapped to target HPV genomes (Supplementary 
Table S2). The MS751 cell line was confirmed not to contain HPV18 sequences (Supplementary Table S1)35.
Deletions in HPV genomes. The method enables identification of regions covered with very few or no 
sequencing reads, interpreted as large HPV genomic deletions. Cell lines HeLa and MS751 are known to contain 
partial HPV genomes due to deletions of 2.5 kb and 5 kb, respectively35,36, which was confirmed by our method 
Figure 1. Primer design, laboratory and bioinformatics workflows of the TaME-seq method.
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(Fig. 2). A large deletion of 4.8 kb was revealed in the clinical sample LBC105, indicating partial or complete dele-
tion of HPV18 genes E1, E2, E4, E5, L1 and L2 (Supplementary Fig. S2).
HPV-human integration sites. A two-step strategy was applied to detect possible integration sites (Fig. 3). 
A total of 27 integration sites were detected in cell lines CaSki, SiHa, HeLa and MS571 (Table 2). For CaSki, 16 
previously reported integration sites30,32,37 were confirmed. In addition, three novel sites were identified. These 
mapped to HPV16 E6, E2 and L1 genes. One was located in an intronic region of the gene BRSK1; two were 
located more than 50 kb from annotated genes (Table 2). Three sites, including one previously reported site as 
a control30,37, were subjected to Sanger sequencing to confirm the integration sites (Supplementary Table S3). 
Integration sites identified in SiHa, HeLa and MS751 were consistent with previous studies31,35–39 and were not 
subjected to validation by Sanger sequencing. Additionally, two integration sites were detected in the clinical sam-
ple LBC105 (Table 2). The integration breakpoints were mapped to the HPV E1 and L1 genes flanking the deleted 
region (Supplementary Fig. S2) and they were located in intronic regions of the gene GTF2IRD1 (Table 2). Both 


















CaSki Cell line 16138790b 12944262 12634651 78% 184716 1.00 1.00
SiHa Cell line 151168b 133360 67496 45% 1018 0.96 0.83
SiHa-1 Cell line 5948008c 3735936 1249594 21% 17561 0.93 0.90
SiHa-1 Cell line 844178b 532874 181199 21% 2554 0.92 0.78
SiHa-2 Cell line 1405886c 789664 420774 30% 5609 0.91 0.85
SiHa-2 Cell line 158672b 90150 48412 31% 646 0.84 0.52
WHO std 
HPV16 Plasmid 359638
b 304002 278987 78% 4104 0.99 0.96
LBC1a LBC 128008b 108756 75323 59% 1124 0.96 0.88
LBC7a LBC 62246b 51590 25567 41% 384 0.94 0.66
HPV18
HeLa Cell line 1433248b 1120824 394420 28% 5897 0.68 0.62
WHO std 
HPV18 Plasmid 2021206
b 1358182 1098783 54% 15447 0.99 0.96
LBC103a LBC 1477706b 1209564 74358 5% 1056 0.93 0.83
LBC105a LBC 190664b 160450 32695 17% 484 0.51 0.34
LBC107 LBC 2180284b 1881868 978435 45% 14663 1.00 0.99
LBC108a LBC 5407154b 3773986 3360463 62% 46691 1.00 0.98
LBC48a LBC 641378b 433884 72589 11% 988 0.95 0.83
HPV31
LBC16 LBC 276994b 191290 74465 27% 1065 0.94 0.80
LBC24a LBC 471666b 348416 24197 5% 355 0.96 0.69
LBC32 LBC 2446832b 1523572 1319939 54% 18983 0.99 0.98
LBC34 LBC 3285680b 1841812 1723631 52% 23790 0.99 0.96
HPV33
HPV33 plasmid Plasmid 13824396b 5202718 5230090 38% 61527 1.00 1.00
LBC11 LBC 2852262b 1052512 986936 35% 12038 0.99 0.98
LBC30 LBC 77128b 51682 21431 28% 303 0.93 0.63
LBC31a LBC 4276740c 2831408 44917 1.1% 544 0.76 0.60
LBC52 LBC 154936b 86990 34390 22% 439 0.95 0.62
LBC65a LBC 368260b 248142 144022 39% 1993 1.00 0.91
HPV45
MS751 Cell line 1221694b 1047286 56291 5% 845 0.35 0.33
LBC13a LBC 496370b 389306 58293 12% 849 0.96 0.78
LBC29 LBC 211052b 122502 45925 22% 614 0.91 0.69
LBC36a LBC 2412532b 1822912 1579570 65% 22093 1.00 0.97
LBC54 LBC 50169422c 26385910 20570184 41% 256857 1.00 1.00
LBC64a LBC 5121416c 3040714 307476 6% 3943 0.95 0.88
Table 1. Read counts and sequencing coverage of HPV positive cell lines, plasmids and LBC samples. 
aSample has multiple HPV infections. bSequenced on MiSeq sequencing platform. cSequenced on HiSeq 2500 
sequencing platform.
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Evaluation of variant calling using SiHa technical replicates. Sequencing libraries of the SiHa cell 
line served as technical replicates to assess the variant calling performance. In both SiHa-1 and SiHa-2, more 
variable sites were detected with higher mean coverage (Fig. 4). Number of variable sites in SiHa-1 ranged from 
477 to 809 and mean coverage ranged from 2554 to 17561. Number of variable sites in SiHa-2 ranged from 257 
to 522 and mean coverage ranged from 646 to 5609 (Fig. 4; Supplementary Table S4). First, reproducibility of 
variant calling was assessed within the same SiHa sequencing library. Concordance rate of variable sites was 
calculated using HiSeq 2500 result as the reference value. The concordance rates varied from 92% (HiSeq down-
sampled 90%) to 45% (MiSeq) in SiHa-1 and from 89% (HiSeq downsampled 90%) to 27% (MiSeq) in SiHa-2 
(Supplementary Table S4). Concordance rates of variants, including low frequency variation, between replicates 
(different library, same sequencing platform) were calculated to evaluate the effect of library preparation steps on 
the number of variable sites found in each sample. Concordance rates were 21% and 19% in SiHa-1 and SiHa-2, 
respectively (Supplementary Table S5).
HPV genomic variability. Variability was analysed in cell lines and LBC samples. Samples had variable sites 
(variant allele frequency >0.2% and coverage ≥100×) in all genes with the exception of regions that were deleted 
or had low sequencing coverage. The number of variable sites was normalised by the length of each HPV genomic 
region. Genomic regions had varying percentages of variable sites (0–28%) in each of the samples. Overall, there 
were samples within each HPV type that had >15% variable sites in at least one HPV gene (Fig. 5). Principally, 
samples with higher mean coverage had more variable sites (Supplementary Table S6), which is in line with the 
results from the variant analysis done on SiHa replicates (Fig. 4). CaSki had most variable sites (1017) of the cell 
lines and LBC54 had most variable sites (1641) of the clinical samples (Supplementary Table S6). A variant profile 
with variable site positions and variant allele frequency (VAF) is shown for CaSki and LBC54 (Fig. 6). Overall, 
the results show considerable variability in the samples throughout the HPV genome (Fig. 5, Supplementary 
Figs S6–S10).
Figure 2. HPV genome sequencing coverage in HPV positive samples. The coverage plots of (a) CaSki, (b) 
HeLa, (c) LBC34, (d) LBC11, and (e) MS751 are aligned to the respective target HPV genomes. The location of 
early (E1, E2, E4-7), late (L1, L2) genes, URR, and forward (red arrows) and reverse (blue arrows) HPV primers 
is indicated below the genomic positions.
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Discussion
Here, we present a novel cost-efficient approach, TaME-seq, for the simultaneous analysis of HPV variation and 
chromosomal integration. Previous methods have been less effective and/or limited to either one of the two 
analyses29–34. To demonstrate the performance of TaME-seq, we employed HPV16, 18, 31, 33 and 45 positive 
clinical samples, HPV positive cell lines and HPV plasmids. With 47% of the total of 154.8 million raw reads 
mapped on the target HPV reference genomes, TaME-seq proved to be highly efficient in HPV target enrichment. 
Other approaches for HPV target enrichment have reported much lower HPV mapping ratios32,40, requiring more 
sequencing and therefore at a higher sequencing cost. TaME-seq currently covers HPV16, 18, 31, 33 and 45, being 
the most common HPV genotypes in cervical cancer5. TaME-seq can be extended to cover additional HPV types, 
as well as other viruses, by implementing new primers to the method.
The ability of TaME-seq to detect chromosomal integration sites has been shown for the HPV positive cervical 
cancer cell lines CaSki, SiHa, HeLa and MS751. CaSki cells contain a high copy number (~600 copies/cell) of 
integrated full-length HPV16 arranged in concatemers41,42. SiHa (1–2 HPV16 copies/cell)39,41 and HeLa (10–50 
HPV18 copies/cell)43 cells harbour integrated HPV genomes. MS751 cells contains integrated HPV4535, but in 
contrast to the product specification sheet (ATCC, Manassas, VA) no HPV18, which was verified in our analyses. 
For CaSki, 16 previously reported integration sites30,32,37 were detected by our method. In addition, three novel 
integration sites were identified. Known integration sites in SiHa31,37,39, HeLa31,36 and MS75135, as well as large 
deletions demonstrated in HeLa36 and MS75135, were confirmed by the TaME-seq method. Of the 21 LBC sam-
ples, HPV integration sites could only be detected in one sample, being in line with previous studies reporting no 
or few HPV integration events in LSIL/ASC-US samples44,45. However, other studies report integration events also 
in LSIL samples32,46. The detection of integrated forms of the virus is also dependent on the amount of episomes 
in the sample; low copy integration sites may remain undetected against a high background of episomal HPV.
The high sequencing coverage throughout the HPV genome enables detection of low frequency variants. 
Variant calling was evaluated using SiHa replicates to set the variant calling threshold. Previous studies have used 
variant calling thresholds of 0.5% or 1%17,34. With the high coverage provided by the TaME-seq method there is 
Figure 3. An IGV visualisation of HISAT2 and LAST alignments to find HPV-human integration breakpoints. 
All the reads were first mapped with HISAT2 and then the unmapped reads were remapped with LAST. (a) SiHa 
reads mapping to chromosome 13 (GRCh38/hg38). Light blue HISAT2 reads have pairs mapping to HPV16 
reference genome. Multi-coloured parts of the LAST reads are mismatched bases that map to HPV16 (not 
visualised). (b) SiHa reads mapping to HPV16 reference genome. Orange HISAT2 reads have pairs mapping 
to chromosome 13 (GRCh38/hg38). Multi-coloured parts of the LAST reads are mismatched bases that map to 
chromosome 13 (not visualised). Red arrows point to the exact breakpoint positions.
www.nature.com/scientificreports/
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Sample










273 E6 20p11.1 chr20:26276796 19 0e
494a E6 20p11.1 chr20:26341342b 7 0e
582 E7 19q13.42 chr19:55310208 0 15
975 E1 Xq27.3 chrX:145696778 0 7
1398 E1 2p23.3 chr2:27135968 6 0e
1793 E1 10p14 chr10:11700197 4 0e
2987 E2 Xq27.3 chrX:145708231 3 8
3239 E2 7p22.1 chr7:6925283 5 0e
3631a E2 19q13.42 chr19:55310043c 3 0e
3729 E2 6p21.1 chr6:45691388 0 11
4654 L2 11p15.4 chr11:6741077 11 0e
5432 L2 11q22.1 chr11:100766632 2 0e
5698 L1 10p14 chr10:11700617 20 0e
5698 L1 5p11 chr5:46292081 2 0e
5762 L1 11q22.1 chr11:100771699 4 0e
6572 L1 19q13.42 chr19:55307445 3 0e
7123a L1 20p11.1 chr20:26357640b 20 0e
7733 URR 11p15.4 chr11:6740842 2 0e
7733 URR 2p23.3 chr2:27137265 6 0e
SiHa
3133 E2 13q22.1 chr13:73513425 7 7
3385 E2/E4 13q22.1 chr13:73214729 3 0e
HPV18
HeLa
2066 E1 8q24.21 chr8:127229053 2 0e
2887 E2 8q24.21 chr8:127221122 13 0e
5730 L1 8q24.21 chr8:127218384 11 89
7655 URR 8q24.21 chr8:127221804 3 0e
LBC105 1561 E1 7q11.23 chr7:74525628d 0 10
LBC105 6528 L1 7q11.23 chr7:74515883d 2 0e
HPV45
MS751
1646 E1 18q11.2 chr18:23024744 10 0e
7120 L1 18q11.2 chr18:23021388 15 0e
Table 2. Chromosomal integration sites detected by TaME-seq. aNovel breakpoint in CaSki cell line. bNo 
annotated genes within 50 kb from the breakpoint. cIntronic region in gene BRSK1. dIntronic region in gene 
GTF2IRD1. eWhen number of unique junction reads is 0, the breakpoint coordinates are not exact.
Figure 4. Number of variable sites in SiHa replicates. SiHa-1 (red dots) and SiHa-2 (blue dots) served as 
technical replicates to assess the variant calling performance. In SiHa libraries, sequenced on MiSeq and HiSeq 
2500 platforms, increasing number of variable sites were detected with higher mean coverage.
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potential for detecting very low frequency variation. We have therefore analysed the variation using 0.2% as the 
variant calling threshold. Multiple and stringent filtering steps was included to filter out non-reliable variants, as 
we are approaching the inherent error rate profile of the PCR amplification and Illumina sequencing47. However, 
the threshold for variant calling is dependent on experimental and analytical basis and must be set according to 
the study aims.
The results from the SiHa analysis indicate that calling ultra-low frequency variants is dependent on the 
sequencing coverage. Lower sequencing coverage results in the detection of fewer variants and less concordance 
between sample replicates. In order to find ultra-low frequency variants, high sequencing coverage is required. 
Figure 4 shows that at the mean coverage of 12000×, the number of variants in SiHa-1 is approaching saturation. 
This indicates that more variants are not likely to be found even with higher sequencing coverage. Finally, dif-
ferences in sequencing coverage affect the number of variable sites found, but also experimental approaches due 
to stochastic sampling and variant calling can fail to reveal low frequency variants. Overall, our results uncover 
low frequency variants in the samples, potentially introduced by DNA repair mechanisms and APOBEC enzyme 
mediated DNA editing48–50, although some bias may be introduced by PCR and sequencing. Variable sites are 
present in all genes of the studied HPV types. Traditionally, studies have focused on sequence variation on a viral 
sublineage level13–16 or the high variability has been interpreted as HPV variant co-infections29. The development 
of NGS technologies has provided comprehensive tools for the study of HPV genomic variability. Recent studies 
have reported high HPV variability that may be evidence of intra-host viral evolution and adaptation generated 
during a chronic HPV infection17–20.
Figure 5. Proportion of variable sites in HPV genes in HPV positive samples. The number of variable sites 
was normalised by the length of each HPV gene. Gradient green (0% variable sites) to red (30% variable sites) 
color-coding of the results is shown to present the considerable variability in the samples throughout the HPV 
genome.
www.nature.com/scientificreports/
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Our study has some limitations. Firstly, TaME-seq is not intended for determining HPV genotypes and we rec-
ommend it for analyses of HPV variability and integration events in samples with known HPV status. Secondly, 
due to variation in amplification efficacy, an uneven coverage is seen for different genomic regions. Sudden drops 
in the coverage, that are not genomic deletions, may be due to suboptimal primer performance or poor alignment 
against the reference genomes. This issue can be solved partly by designing new primers covering these regions 
and optimising the primer performance. Also, the read alignment step can be further optimised. Alternatively, 
alignment could be performed by de novo assembly to create consensus sequences for the alignment. Thirdly, 
enough viral DNA and good dsDNA quality are important for achieving consistent tagmentation results in the 
Nextera protocol51. Sample preparation of the excluded LBC samples failed likely due to very low viral load in the 
samples, which was not quantified separately.
In summary, we have developed a NGS approach that allows the simultaneous study of HPV genomic variabil-
ity and chromosomal integration. TaME-seq is applicable to large sample cohorts due to its highly efficient target 
enrichment, leading to less off-target sequences and therefore reduced sequencing cost. Comprehensive studies 
on HPV intra-host variability generated during a persistent infection will improve our understanding of viral 
carcinogenesis. Efficient identification of HPV genomic variability and integration sites will be important both for 
the study of HPV evolution, adaptability and may be a useful tool for cervical cancer diagnostics.
Methods
Samples. Anonymised LBC samples from routine cervical cancer screening were included in the study, 
comprising cases of atypical squamous cells of undetermined significance (ASC-US) and low-grade squamous 
intraepithelial lesions (LSIL). HPV positive samples with the cobas 4800 HPV test (Roche Molecular Diagnostics, 
Pleasanton, CA) were extracted for DNA using the automated system NucliSENS easyMAG (BioMerieux Inc., 
France) with off-board lysis. The samples were HPV genotyped using the modified GP5+/6+ PCR protocol 
(MGP)52, followed by HPV type-specific hybridisation using Luminex suspension array technology53 or the 
Anyplex™ II HPV28 assay (Seegene, Inc., Seoul, Korea). LBC samples (n = 31) were positive for HPV16, 18, 31, 
33 or 45 alone, or had multiple infections including at least one of the five types. DNA extracted from the HPV 
positive cervical carcinoma cell lines CaSki, SiHa, HeLa and MS751 (ATCC, Manassas, VA) served as positive 
controls. WHO international standards for HPV 16 (1st WHO International Standard for Human Papillomavirus 
Type 16 DNA, NIBSC code: 06/202) and 18 (1st WHO International Standard for Human Papillomavirus Type 18 
Figure 6. HPV nucleotide variation observed in two samples. The plots showing variable sites and variant allele 
frequency (%) in (a) CaSki, and (b) LBC54 are aligned to the respective target HPV genomes. The location of 
genes and URR is indicated below the genomic positions. The red line indicates the variant calling threshold 
value of 0.2%.
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DNA, NIBSC code: 06/206)(NIBSC, Potters Bar, Hertfordshire, UK) and a plasmid containing the strain HPV3354 
were used as additional positive controls. Laboratory-grade water and DNA from an HPV negative human sam-
ple were included as negative controls. DNA was quantified by the fluorescence-based Qubit dsDNA HS assay 
(Thermo Fisher Scientific Inc.,Waltham, MA, USA).
Primer design. HPV16, 18, 31, 33, and 45 whole genome reference and variant sequences were obtained 
from the PapillomaVirus Episteme (PaVE) database55. All the available reference and variant sequences within 
an HPV type were aligned using the multiple sequence alignment tool ClustalO56. The sequence alignment 
was converted to a consensus sequence for each HPV type in CLC Sequence viewer version 7.7.1 (QIAGEN 
Aarhus A/S). TaME-seq HPV primers were designed using Primer357 and HPV consensus sequences as 
the source sequence. Finally, primers were modified by adding an Illumina TruSeq-compatible adapter tail 
(5′-AGACGTGTGCTCTTCCGATCT-3′) to the 5′-end and then synthesised by Thermo Fisher Scientific, Inc. 
(Waltham, MA).
Library preparation and sequencing. Primer pools for each HPV type were prepared by combining 
primers separately in equal volumes. Samples were subjected to tagmentation using Nextera DNA library prep kit 
(Illumina, Inc., San Diego, CA). Tagmented DNA was purified using DNA Clean & Concentrator™-5 columns 
(Zymo Research, Irvine, CA) according the manufacturer’s instructions or ZR-96 DNA Clean & Concentrator™-5 
plates (Zymo Research, Irvine, CA) according to the Nextera® DNA Library Prep Reference Guide (15027987 
v01) before PCR amplification for target enrichment. Amplification was performed using Qiagen Multiplex PCR 
Master mix (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. For each sample, two PCR 
reactions were performed separately with 0.75 µM of HPV primer pools, 0.5 µM of i7 index primers (adapted 
from Kozich et al.58) and 1 µl of i5 index primers from the Nextera index kit (Illumina, Inc., San Diego, CA). The 
cycling conditions were as follows: initial denaturation and hot start at 95 °C for 5 minutes; 30 cycles at 95 °C for 
30 seconds, at 58 °C for 90 seconds and at 72 °C for 20 seconds; final extension at 68 °C for 10 minutes. Following 
amplification, libraries were pooled in equal volumes and the final sample pool was purified with Agencourt® 
AMPure® XP beads (Beckman Coulter, Brea, CA). The quality and quantity of the pooled libraries were assessed 
on Agilent 2100 Bioanalyzer using Agilent High Sensitivity DNA Kit (Agilent Technologies Inc., Santa Clara, CA) 
and by qPCR using KAPA DNA library quantification kit (Kapa Biosystems, Wilmington, MA). Sequencing was 
performed on the MiSeq platform (Illumina, Inc., San Diego, CA) or on the HiSeq 2500 platform (Illumina, Inc., 
San Diego, CA). Samples were sequenced as 151 bp paired-end reads and two 8 bp index reads.
Sequence alignment. Raw paired-end reads were trimmed for adapters, HPV primers, quality (-q 20) 
and finally for minimum length (-m 50) using cutadapt (v1.10)59. Trimmed reads were mapped to human 
(GRCh38/hg38) and HPV16, 18, 31, 33 and 45 reference genomes obtained from the PaVE database55 using 
HISAT2 (v2.1.0)60. Mapping statistics and sequencing coverage were calculated using the Pysam package61 with 
an in-house Python (v3.5.4) script. Downstream analysis was performed using an in-house R (v3.4.4) script. 
Results from both reactions of the same sample were combined and method performance was then evaluated 
based on the percentage of obtained reads mapped to the HPV reference genome, mean sequencing coverage and 
percentage of HPV reference genome coverage for each sample. Further analysis was performed when a sample 
had >20000 reads mapped to the target HPV reference genome. The target HPV genomes correspond to the HPV 
types for which the samples were reported positive by HPV genotyping.
Detecting HPV-human integration sites. The paired-end reads that mapped (HISAT2) with one end to 
a human chromosome and the other end to the target HPV reference genome were identified as discordant read 
pairs. If a specific position had ≥2 read pairs with unique start or end coordinates, it was considered as a potential 
integration site. To determine the exact position of HPV-human integration breakpoints, previously unmapped 
reads were remapped to human and HPV reference genomes (as above) using the LAST (v876) aligner (options 
-M -C2)62. Positions covered by ≥3 junction reads, with unique start or end coordinates, were considered as 
potential integration breakpoints. Integration site detection was not based on reads sharing the same start and 
end coordinates as these reads were considered as potential PCR duplicates. Selected HPV integration break-
points were confirmed by PCR amplification and Sanger sequencing.
Sequence variation analysis. Mapped nucleotide counts over HPV reference genomes and average map-
ping quality values of each nucleotide were retrieved from BAM files and variant calling was performed using an 
in-house R script. To reduce the effects of PCR amplification and sequencing artefacts in the variation analysis, 
filtering was applied before the variant calling. Nucleotides seen ≤2 times in each position and nucleotides with 
mean Phred quality score of <20 were filtered out. Nucleotide counts from both reactions of the same sample 
were combined and variant allele frequencies (VAF) of the three minor alleles in each position were calculated. If 
results from either of the reaction showed >5 times larger VAF with <20% of the total coverage, it was discarded 
from variant calling. Finally, variants were called if VAF was >0.2% and coverage was ≥100×.
Two sequencing libraries of SiHa cell line served as technical replicates to assess the variant calling perfor-
mance. The technical replicates were sequenced on the MiSeq platform or on the HiSeq 2500 platform. In addi-
tion, HiSeq raw sequencing data was downsampled randomly and defined portions (90%, 75%, 50% and 25%) 
of the original reads were further analysed. Reproducibility of calling variants in the replicates was assessed by 
calculating concordance rate. The concordance rate (Rc) between duplicates was defined as follows:
=R N
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where Nc was the number of concordant variants between a pair of replicate samples, and N1 and N2 were the total 
number of variants detected in each of the duplicated sample.
Ethical approval. This study was approved by the regional committee for medical and health research ethics, 
Oslo, Norway [2017/447] and we confirm that all experiments were performed in accordance with the commit-
tee’s guidelines and regulations.
Data Availability
Sequence data from cell lines will be available at European Nucleotide Archive (ENA) accession number 
ERP111061. Plasmids are third party property and requests must be made to International Human Papilloma-
virus Reference Center and Institut Pasteur. Sequencing data from clinical samples will be available from the 
authors upon request with obtained ethical approval. Clinical sequence data may be deposited at the European 
Genome-phenome Archive (EGA) (ethical and legal assessments are on-going).
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